SAN FRANCISCO (AP) _ Nektar Therapeutics (NKTR) on Thursday reported a loss of $90.4 million in its first quarter.

The San Francisco-based company said it had a loss of 49 cents per share.

The results surpassed Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for a loss of 72 cents per share.

The biopharmaceutical company posted revenue of $24.8 million in the period, also topping Street forecasts. Six analysts surveyed by Zacks expected $24 million.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on NKTR at https://www.zacks.com/ap/NKTR

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News